Natalia N Nalivaeva

List of Publications by Year
in descending order

63 papers	2,681 citations	201385 27 h-index	189595 50 g-index
63 all docs	63 docs citations	63 times ranked	3525 citing authors

#	Article	IF	Citations
1	Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides, 2022, 151, 170766.	1.2	20
2	Caspase Inhibition Restores NEP Expression and Rescues Olfactory Deficit in Rats Caused by Prenatal Hypoxia. Journal of Molecular Neuroscience, 2022, , 1.	1.1	1
3	Lactoferrin Induces Erythropoietin Synthesis and Rescues Cognitive Functions in the Offspring of Rats Subjected to Prenatal Hypoxia. Nutrients, 2022, 14, 1399.	1.7	9
4	Developmental Profile of Brain Neprilysin Expression Correlates with Olfactory Behaviour of Rats. Journal of Molecular Neuroscience, 2021, 71, 1772-1785.	1.1	10
5	Effect of Global Brain Ischemia on Amyloid Precursor Protein Metabolism and Expression of Amyloid-Degrading Enzymes in Rat Cortex: Role in Pathogenesis of Alzheimerâ€™s Disease. Biochemistry (Moscow), 2021, 86, 680-692.	0.7	6
6	Glucocorticoid-Dependent Mechanisms of Brain Tolerance to Hypoxia. International Journal of Molecular Sciences, 2021, 22, 7982.	1.8	13
7	Neprilysin expression and functions in development, ageing and disease. Mechanisms of Ageing and Development, 2020, 192, 111363.	2.2	89
8	Molecular Mechanisms of Cognitive Impairment and Intellectual Disabilityâ€”Virtual ESN Mini-Conference in Conjunction with the FENS Forum, July 11â€“15, 2020. Journal of Molecular Neuroscience, 2020, 70, 1927-1933.	1.1	1
9	Editorial: Brain Hypoxia and Ischemia: New Insights Into Neurodegeneration and Neuroprotection. Frontiers in Neuroscience, 2019, 13, 770.	1.4	14
10	Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. British Journal of Pharmacology, 2019, 176, 3447-3463.	2.7	115
11	Special Issue in Honour of Anthony J (Tony) Turner. Neurochemical Research, 2019, 44, 1269-1270.	1.6	0
12	Age-Dependent Electrocorticogram Dynamics and Epileptogenic Responsiveness in Rats Subjected to Prenatal Hypoxia. Developmental Neuroscience, 2019, 41, 56-66.	1.0	5
13	Role of Prenatal Hypoxia in Brain Development, Cognitive Functions, and Neurodegeneration. Frontiers in Neuroscience, 2018, 12, 825.	1.4	110
14	Ontogenetic and Phylogenetic Approaches for Studying the Mechanisms of Cognitive Dysfunctions. , 2018, , .		4
15	Role of Ageing and Oxidative Stress in Regulation of Amyloid-Degrading Enzymes and Development of Neurodegeneration. Current Aging Science, 2017, 10, 32-40.	0.4	29
16	AChE and the amyloid precursor protein (APP) â€“ Cross-talk in Alzheimer's disease. Chemico-Biological Interactions, 2016, 259, 301-306.	1.7	45
17	Reflections on 60Âyears of publication of the Journal of Neurochemistry. Journal of Neurochemistry, 2016, 139, 7-16.	2.1	4
18	New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes. Neurochemical Research, 2016, 41, 620-630.	1.6	20

#	Article	IF	Citations
19	Role of amyloid precursor protein (APP) in regulation of neuronal genes. SpringerPlus, 2015, 4, L40.	1.2	1
20	Hypoxia Affects Neprilysin Expression Through Caspase Activation and an APP Intracellular Domain-dependent Mechanism. Frontiers in Neuroscience, 2015, 9, 426.	1.4	43
21	Role of caspase-3 in development of neuronal plasticity and memory. SpringerPlus, 2015, 4, .	1.2	1
22	Effect of hypoxia on cholinesterase activity in rat sensorimotor cortex. Journal of Evolutionary Biochemistry and Physiology, 2015, 51, 107-116.	0.2	6
23	Effects of ageing and experimental diabetes on insulin-degrading enzymeÂexpressionÂin male rat tissues. Biogerontology, 2015, 16, 473-484.	2.0	32
24	Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 235.	1.7	88
25	The AÎ²â€clearance protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain. Journal of Neurochemistry, 2014, 130, 419-431.	2.1	64
26	The Amyloid Precursor Protein Represses Expression of Acetylcholinesterase in Neuronal Cell Lines. Journal of Biological Chemistry, 2013, 288, 26039-26051.	1.6	19
27	Characterisation of acetylcholinesterase release from neuronal cells. Chemico-Biological Interactions, 2013, 203, 302-308.	1.7	15
28	From synaptic spines to nuclear signaling: nuclear and synaptic actions of the amyloid precursor protein. Journal of Neurochemistry, 2013, 126, 183-190.	2.1	44
29	The amyloid precursor protein: A biochemical enigma in brain development, function and disease. FEBS Letters, 2013, 587, 2046-2054.	1.3	196
30	Peptide Degradation (Neprilysin and Other Regulatory Peptidases). , 2013, , 1757-1764.		4
31	Neprilysin. , 2013, , 612-619.		8
32	Lipid Rafts and Alzheimerâ€™s Disease: Protein-Lipid Interactions and Perturbation of Signaling. Frontiers in Physiology, 2012, 3, 189.	1.3	161
33	Differential expression of ADAM15 and ADAM17 metalloproteases in the rat brain after severe hypobaric hypoxia and hypoxic preconditioning. Neuroscience Research, 2012, 72, 364-373.	1.0	17
34	Are amyloidâ€degrading enzymes viable therapeutic targets in Alzheimerâ€™s disease?. Journal of Neurochemistry, 2012, 120, 167-185.	2.1	161
35	Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cellular Signalling, 2012, 24, 402-409.	1.7	71
36	Effect of Sodium Valproate Administration on Brain Neprilysin Expression and Memory in Rats. Journal of Molecular Neuroscience, 2012, 46, 569-577.	1.1	71

#	Article	IF	Citations
37	Membrane targeting, shedding and protein interactions of brain acetylcholinesterase. Journal of Neurochemistry, 2011, 116, 742-746.	2.1	36
38	The Fourth ISN Special Neurochemistry Conference -â€œMembrane domains in CNS Physiology and Pathologyâ€, Erice, Trapani, Sicily, 22-26 May 2010. Journal of Neurochemistry, 2011, 116, 669-670.	2.1	1
39	Mediator: the missing link in amyloid precursor protein nuclear signalling. EMBO Reports, 2011, 12, 180-181.	2.0	8
40	Effects of geroprotective peptides on the activity of cholinesterases and formation of the soluble form of the amyloid precursor protein in human neuroblastoma SH-SY5Y cells. Neurochemical Journal, 2011, 5, 176-182.	0.2	3
41	Metalloproteases and Proteolytic Processing. , 2011, , 457-482.		1
42	Changes in the Activity of Amyloid-Degrading Metallopeptidases Leads to Disruption of Memory in Rats. Neuroscience and Behavioral Physiology, 2010, 40, 975-980.	0.2	5
43	Co-localization of PRiMA with acetylcholinesterase in cholinergic neurons of rat brain: An immunocytochemical study. Brain Research, 2010, 1344, 34-42.	1.1	13
44	The Transcriptionally Active Amyloid Precursor Protein (APP) Intracellular Domain Is Preferentially Produced from the 695 Isoform of APP in a Î²-Secretase-dependent Pathway. Journal of Biological Chemistry, 2010, 285, 41443-41454.	1.6	175
45	Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Reports, 2009, 10, 94-100.	2.0	151
46	Sodium valproate: an old drug with new roles. Trends in Pharmacological Sciences, 2009, 30, 509-514.	4.0	88
47	Prenatal hypoxia affects amyloid metabolism and formation of cognitive functions in postnatal ontogenesis of rats. International Journal of Psychophysiology, 2008, 69, 156.	0.5	0
48	Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease. Current Alzheimer Research, 2008, 5, 212-224.	0.7	159
49	Antidepressant-like effects of mild hypoxia preconditioning in the learned helplessness model in rats. Neuroscience Letters, 2007, 417, 234-239.	1.0	36
50	New Insights into the Roles of Metalloproteinases in Neurodegeneration and Neuroprotection. International Review of Neurobiology, 2007, 82, 113-135.	0.9	64
51	Involvement of the hypothalamic-pituitary-adrenal axis in the antidepressant-like effects of mild hypoxic preconditioning in rats. Psychoneuroendocrinology, 2007, 32, 813-823.	1.3	34
52	Effects of Hypoxia and Oxidative Stress on Expression of Neprilysin in Human Neuroblastoma Cells and Rat Cortical Neurones and Astrocytes. Neurochemical Research, 2007, 32, 1741-1748.	1.6	103
53	Regulation of endothelin-converting enzyme-1 expression in human neuroblastoma cells. Experimental Biology and Medicine, 2006, 231, 1048-53.	1.1	8
54	Targeting Amyloid-Degrading Enzymes as Therapeutic Strategies in Neurodegeneration. Annals of the New York Academy of Sciences, 2004, 1035, 1-20.	1.8	73

#	Article	IF	Citations
55	Effect of Hypoxia/Ischemia and Hypoxic Preconditioning/Reperfusion on Expression of Some Amyloid-Degrading Enzymes. Annals of the New York Academy of Sciences, 2004, 1035, 21-33.	1.8	88
56	Effects of prenatal hypoxia on expression of amyloid precursor protein and metallopeptidases in the rat brain. International Journal of Peptide Research and Therapeutics, 2003, 10, 455-462.	0.1	17
57	Effects of prenatal hypoxia on expression of amyloid precursor protein and metallopeptidases in the rat brain. International Journal of Peptide Research and Therapeutics, 2003, 10, 455-462.	0.9	2
58	Post-translational modifications of proteins: Acetylcholinesterase as a model system. Proteomics, 2001, 1, 735-747.	1.3	83
59	Post-translational modifications of proteins: Acetylcholinesterase as a model system. , 2001, 1, 735.		2
60	ACTIVATION OF NEUTRAL SPHINGOMYELINASE BY IL-1Î² REQUIRES THE TYPE 1 INTERLEUKIN 1 RECEPTOR. Cytokine, 2000, 12, 229-232.	1.4	26
61	Does acetylcholinesterase secretion involve an ADAMs-like metallosecretase?. International Journal of Peptide Research and Therapeutics, 1999, 6, 343-348.	0.1	0
62	Does acetylcholinesterase secretion involve an ADAMs-like metallosecretase?. International Journal of Peptide Research and Therapeutics, 1999, 6, 343-348.	0.1	6
63	Involvement of the sphingomyelinin pathway in interleukin 1 signalling in murine immunocompetent and nerve cells. Immunology Letters, 1997, 56, 67.	1.1	2